Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Bill & Melinda Gates Foundation

Q2 2023 · 13F-HR

Bill & Melinda Gates Foundationholdings as filed

Filed 2023-08-14 · accession 0000898432-23-000623

$125.6M
Reported value
9
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
92764N102VIRVIR BIOTECHNOLOGY INC$38.2M30.4%1,559,142CommonSOLE
45258D105IMCRIMMUNCORE HLDGS PLC$34.6M27.5%576,923CommonSOLE
N2451R105CVACCUREVAC N V$16.9M13.5%1,625,943CommonSOLE
09075V102BNTXBIONTECH SE$16.0M12.8%148,674CommonSOLE
30223G102EXAIEUREXSCIENTIA$9.4M7.50%1,590,909CommonSOLE
G5709L109LUMIRADX LTD$6.9M5.46%14,285,714CommonSOLE
124155102BFLYBUTTERFLY NETWORK INC$2.3M1.85%1,011,003CommonSOLE
04965G109BCELUSDATRECA INC$913,1790.73%931,815CommonSOLE
03236M200AMYRIS INC$301,1700.24%292,398CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.